Abstract: A method of automatically displaying a predetermined set of print attributes of a print job, the method including receiving an image of a first printed sheet, the first printed sheet including one or more at least partial machine-readable codes, the one or more at least partial machine-readable codes encoded with data related to the predetermined set of print attributes, decoding the data from the one or more at least partial machine-readable codes, determining if the data includes all of the print attributes in the predetermined set of print attributes, and if the data includes all of the print attributes in the predetermined set of print attributes, displaying the data using augmented reality (AR) over the first printed sheet.

Abstract: The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling weeds, in particular in crops of useful plants.

Abstract: Disclosed is a sealing composition for treating a metal substrate comprising: a polyolefin component; and a colloidal layered silicate. Also disclosed is a system for treating a metal substrate comprising: a cleaner composition; and/or a pretreatment composition for treating at least a portion of the substrate, the pretreatment composition comprising a Group IVB metal; and a sealing composition for treating at least a portion of the substrate treated with the cleaner composition and/or the pretreated composition, the sealing composition comprising a polyolefin component. Also disclosed is a method of treating a substrate comprising contacting at least a portion of a surface of the substrate with any of the compositions disclosed herein or any of the systems disclosed herein.

Abstract: The present strains and methods of the disclosure relate to genetic modifications in filamentous fungi that give rise to variant strains having altered phenotypes, altered morphologies, altered growth characteristics, and the like. More specifically, as presented and described herein, such variant strains of filamentous fungi comprising reduced viscosity phenotypes are well-suited for growth in submerged cultures (e.g., for the large-scale production of enzymes and other proteins or metabolites for commercial applications).

Abstract: A container having a base and a lid is provided. The lid may be rotatable about a hinge from a closed configuration to an open configuration and may be secured, via one or more latching assemblies. The latch assembly may comprise a latch body, a locking member, a biasing member, and an activating member. The lid may have a handle that has a stowed and a carry position, where the handle may be maintained in the stowed position until acted upon by a first force greater than a threshold force to move the handle from the stowed position to the carry position. Similarly, when in the carry position, the handle may be maintained in the carry position until acted upon by a second force greater than the threshold force to move the handle from the carry position to the stowed position.

Abstract: Printing system and method for reducing the visibility of gloss differentials having at least one computer-supported inline imaging unit assembly designed to measure specular light reflecting gloss differentials of printed ink. At least one smoothing roller assembly is operationally connected to at least one sheet transport assembly or a smoothing transport subassembly of the sheet transport assembly of the printing system. A smoothing roller assembly is designed to roll at least partly the length and width of at least one printed side of at least one printed sheet disposed along the transport subassembly, pressure generated by the smoothing roller assembly configured to reduce detected gloss differentials from printed ink. At least the outer surface of the at least one smoothing roller assembly is substantially at least one or more of metal and polyurethane.

Abstract: A system implements a surge protection bus bar. The system includes a surge protection device that includes a connection point. The system further includes a carrier assembly juxtaposed to the surge protection device. The carrier assembly includes an interconnection point, an attachment point, and a rigid bar connecting between an interconnection point and the attachment point. A proximal end of the rigid bar integrally forms the interconnection point and a distal end of the rigid bar includes the attachment point.

Abstract: A pressure-sensing device includes a device frame, a flexible membrane, a pressure sensor, and device electronics. The device frame includes a base surface that rests on a supporting structure and a frame attachment region located opposite to the base surface such that the frame attachment region is raised from the supporting structure when the base surface is resting on the supporting structure. The device frame also includes a seating surface. The flexible membrane is attached to the frame attachment region such that the device frame and the flexible membrane enclose a pressure chamber. The seating surface extends outward around the flexible membrane and the flexible membrane protrudes above the seating surface. The pressure sensor is configured to generate a pressure signal. The device electronics are configured to determine the pressure in the pressure chamber based on the pressure signal.

Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W—X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

Abstract: A thermal device includes a first thermal unit, a second thermal unit, and device electronics. The first thermal unit includes a first plurality of semiconductor elements sandwiched between first and second thermal unit substrates. The first thermal unit substrate exchanges heat with a user. The second thermal unit includes a second plurality of semiconductor elements sandwiched between third and fourth thermal unit substrates. The third thermal unit substrate exchanges heat with the user. The device electronics are coupled to the first thermal unit and the second thermal unit. The device electronics operate the first thermal unit in a heating state in which the first thermal unit transfers heat to the user via the first thermal unit substrate. The device electronics operate the second thermal unit in a cooling state in which the second thermal unit removes heat from the user via the third thermal unit substrate.

Abstract: The present invention is directed to an electrodepositable coating composition comprising an electrodepositable binder comprising an ionic salt group-containing film-forming polymer comprising active hydrogen functional groups, and a blocked polyisocyanate curing agent; a solubilized bismuth catalyst; and a guanidine; wherein the electrodepositable coating composition has a weight ratio of bismuth metal from the solubilized bismuth catalyst to guanidine of from 1.00:0.071 to 1.0:2.1 and/or a molar ratio of bismuth metal to guanidine of from 1.0:0.25 to 1.0:3.0. Also disclosed are methods of treating electrodepositable coating compositions, methods for making electrodepositable coating compositions, systems for coating a metal substrate, coatings, coated substrates, and methods of coating a substrate.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Abstract: A container having a base and a lid is provided. The lid may be rotatable about a hinge from a closed configuration to an open configuration and may be secured, via one or more latching assemblies. The latch assembly may comprise a latch body, a locking member, a biasing member, and an activating member. The lid may have a handle that has a stowed and a carry position, where the handle may be maintained in the stowed position until acted upon by a first force greater than a threshold force to move the handle from the stowed position to the carry position. Similarly, when in the carry position, the handle may be maintained in the carry position until acted upon by a second force greater than the threshold force to move the handle from the carry position to the stowed position.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.